MACHEREY-NAGEL GmbH & Co. KG

Macherey-Nagel specializes in in-vitro diagnostic (IVD) devices, primarily focused on urine analysis. Their product range includes test strips for detecting pH levels, glucose, leukocytes, and other urine chemistry markers, as well as handheld analyzers for rapid urine testing. They also produce nucleic acid extraction kits for pathogen detection, which are used in laboratory settings to identify specific microorganisms. These devices are designed for both point-of-care and clinical laboratory use.

Macherey-Nagel is headquartered in Germany, which means its devices must comply with European Union regulations, including those outlined in the In Vitro Diagnostic Regulation (IVDR). Since the company’s products are listed in eudamed, they are registered under the EU’s regulatory framework. Additionally, some of their devices are also included in the FDA’s 510(k) premarket notification registry, indicating they are also authorised for the US market under Class II classification.

Macherey-Nagel’s devices appear in eudamed, the EU’s centralised database for IVD manufacturers, and the FDA’s 510(k) registry, which tracks US-authorised medical devices. Listing in these registries confirms that the manufacturer has met the necessary regulatory requirements for market authorisation in both the European Union and the United States. This transparency helps healthcare providers, regulators, and distributors verify compliance and traceability of the devices.

Macherey-Nagel’s devices fall under EU Class A, B, and C classifications, depending on their risk level and intended use, such as general urine chemistry tests (Class A/B) or more complex diagnostic assays (Class C). In the US, their devices are classified under Class II, which requires premarket notification (510(k)) to demonstrate substantial equivalence to a predicate device. The classification determines the regulatory pathway and scrutiny required for market authorisation.